## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.4% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($45.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus**
- Source: ts2.tech | 20251130T003632 | Neutral | Relevance: 100%
- This article examines Bristol-Myers Squibb (BMY) stock as of November 29, 2025, highlighting its 5.4% dividend yield, significant institutional buying, and a general "Hold" consensus from Wall Street analysts. It delves into the company's performance, valuation, dividend debate amidst patent cliffs and regulatory pressures, and recent strategic moves, while also outlining key risks and what the news means for investors.

**2. Bristol Myers Squibb (BMY) Is Up 6.4% After EU Approves Breyanzi for Mantle Cell Lymphoma**
- Source: Simply Wall Street | 20251130T081745 | Somewhat-Bullish | Relevance: 99%
- Bristol Myers Squibb's stock rose 6.4% after the European Commission approved Breyanzi for relapsed or refractory mantle cell lymphoma, expanding its oncology portfolio in Europe. While this approval is positive for the company's late-stage innovation and pipeline strength, it does not alleviate the immediate risk from impending patent expirations for key drugs like Eliquis and Opdivo. The company is projected to generate $41.3 billion in revenue and $9.2 billion in earnings by 2028, with a forecasted annual revenue decline partially offset by increased earnings.

**3. Panagora Asset Management Inc. Sells 284,931 Shares of Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251202T123154 | Neutral | Relevance: 99%
- Panagora Asset Management Inc. reduced its stake in Bristol Myers Squibb Company by 10.3%, selling 284,931 shares during the Q2. Following this, Panagora now owns 2,492,859 shares worth approximately $115.4 million. Additionally, EVP David V. Elkins sold 56,000 shares, decreasing his ownership by over 25%.

**4. BMY Gains Attention as Bayer Reports FXIa Trial Success**
- Source: Insider Monkey | 20251130T142700 | Neutral | Relevance: 99%
- Bristol-Myers Squibb (NYSE: BMY) is gaining attention after Bayer reported positive Phase 3 results for its FXIa inhibitor, asundexian, potentially increasing interest in similar treatments. While BMY is not experiencing significant growth, it remains profitable with a sustainable payout ratio of around 84% and strong free cash flow generation. However, concerns about its $32 billion net debt could impact future dividend safety despite a recent reduction.

**5. XTX Topco Ltd Buys New Shares in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251201T131929 | Neutral | Relevance: 99%
- XTX Topco Ltd initiated a new position in Bristol Myers Squibb (NYSE: BMY) during Q2, acquiring 23,233 shares valued at approximately $1.08 million. Institutional investors collectively own about 76.41% of the stock. The company's stock currently holds an average consensus rating of "Hold" with an average target price of $54.42, and paid a 5.0% dividend yield.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $104.3B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.1 |
| Current P/E | 7.4 |
| YoY Growth | -8.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.3% to -1.4% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.98x), long-term trend not supportive. RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.42% (CS: 47) | Neutral |
| RSI_14 | 57.6 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 0.982x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $48.25
- **Stop Loss:** $45.93 (4.8% risk)
- **Target:** $50.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 431
- **Position Value:** $20,795.75
- **Portfolio %:** 20.80%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*